Influence of Prolonged Duration of Symptoms Before MIS-TLIF in a Workers' Compensation Population.


Journal

World neurosurgery
ISSN: 1878-8769
Titre abrégé: World Neurosurg
Pays: United States
ID NLM: 101528275

Informations de publication

Date de publication:
Jul 2023
Historique:
received: 27 01 2023
revised: 27 03 2023
accepted: 28 03 2023
medline: 28 6 2023
pubmed: 7 4 2023
entrez: 6 4 2023
Statut: ppublish

Résumé

We assessed the potential effect of the preoperative symptom duration on patient-reported outcomes (PROs) for workers' compensation (WC) patients undergoing minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF). WC patients who had undergone primary, elective MIS-TLIF with recorded symptoms duration data available were included. Two cohorts were generated: those with a shorter (lesser) duration (LD; symptom duration <1 year) and those with a prolonged duration (PD; symptom duration >1 year). PROs were collected preoperatively and at several follow-up points for ≤1 year postoperatively. The PROs were compared within and between the 2 cohorts. The achievement rates of minimum clinically important differences were also compared between the 2 cohorts. A total of 145 patients were included, with 76 in the PD cohort and 69 in the LD cohort. The LD cohort demonstrated improvement in the patient-reported outcomes measurement information system for physical function (PROMIS-PF) at 6 months and 1 year postoperatively, Oswestry disability index (ODI) at 12 weeks and 6 months postoperatively, visual analog scale (VAS) score for back pain at 6 weeks, 12 weeks, and 6 months postoperatively, and VAS score for leg pain at all postoperative points (P ≤ 0.015 for all). The PD cohort demonstrated improvement in the PROMIS-PF at 12 weeks and 6 months postoperatively, ODI at 6 weeks, 12 weeks, and 6 months postoperatively, and VAS score for back pain and leg pain at all postoperative periods (P ≤ 0.007 for all). All the preoperative PROs were superior for the LD cohort (P < 0.001 for all). The LD cohort reported better PROMIS-PF at 6 months and 1 year and ODI at 1 year postoperatively (P ≤ 0.037 for all). The PD cohort was more likely to achieve a minimum clinically important difference in ODI at 6 and 12 weeks postoperatively, VAS score for back pain at 6 weeks postoperatively, and VAS score for leg pain at 6 weeks and 1 year postoperatively and overall (P ≤ 0.036 for all). Independently of the preoperative symptom duration, WC patients demonstrated improvement in physical function and pain after MIS-TLIF. Patients with a longer symptom duration reported inferior function and pain preoperatively and were more likely to demonstrate clinically significant improvements in disability and pain postoperatively.

Identifiants

pubmed: 37024079
pii: S1878-8750(23)00444-8
doi: 10.1016/j.wneu.2023.03.120
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e439-e446

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Auteurs

Timothy J Hartman (TJ)

Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, Illinois, USA.

James W Nie (JW)

Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, Illinois, USA.

Eileen Zheng (E)

Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, Illinois, USA.

Keith R MacGregor (KR)

Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, Illinois, USA.

Omolabake O Oyetayo (OO)

Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, Illinois, USA.

Vincent P Federico (VP)

Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, Illinois, USA.

Dustin H Massel (DH)

Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, Illinois, USA.

Arash J Sayari (AJ)

Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, Illinois, USA.

Kern Singh (K)

Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, Illinois, USA. Electronic address: kern.singh@rushortho.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH